

The Chemical Conversion of C-Terminal Glycines in Peptides into Taurine

Kunihiko Higashiura, Yoshio Toyomaki, and Kazuharu Ienaga*


Institute of Bio-Active Science (IBAS), Nippon Zoki Pharmaceutical Co. Ltd., Kinashi, Yashiro-cho, Kato-gun, Hyogo 673-14, Japan

The first chemical conversion of C-glycine in dipeptides into taurine has been achieved using a general substitution of a sulpho group for a halogeno or mesyl group *via* the corresponding amino acid 2-halogenoethyl- or 2-methanesulphonyloxyethyl-amides, each of which was prepared from the ethanolamide obtained by LiBH_4 reduction of a protected dipeptide containing a C-glycine ester.

Although taurine itself has been thoroughly investigated, studies on its derivatives such as taurine-peptides have been limited. However, the discovery of γ -Glu-Tau (glutaurine) in mammalian parathyroids¹ promoted studies on such intrinsic taurine-peptides.¹⁻³ Several synthetic studies,⁴⁻⁸ mostly based on conventional coupling of taurine with an amino acid or peptide, have also been documented. During our studies on the immunocross reactivities of a series of taurine-oligopeptides with haptenic taurine- and glutaurine-antisera,^{3,7-10} we have previously shown^{7,8} that substitution *via* amino acid β -halogenoethylamides is useful as an alternative general synthetic method without racemization. Since a C-terminal glycine can therefore be a precursor of a 2-hydroxyethylamide¹¹ which can be converted to the halogenoethylamide, we have combined these independent techniques into a conversion route from glycine-peptide to taurine-peptide.

Boc-Val-Gly-OEt (**1a**) (50 mmol) was reduced (Scheme 1) in ethanol (140 ml) to give crystalline Boc-Val-NHCH₂CH₂OH (**2a**), m.p. 89–90 °C, in 95% yield by using LiBH_4 ,¹¹ prepared from NaBH_4 (100 mmol) and LiCl (100 mmol) in tetrahydrofuran (THF) (70 ml). The ethanolamide (**2a**) was converted to an intermediate, Boc-Val-NHCH₂CH₂OMs (**3a**), m.p. 87–89 °C, by reaction of the ethanolamide (**2a**) and methanesulphonylchloride (50 mmol) with triethylamine (52 mmol) in dichloromethane (200 ml) in 90% yield. Val-Tau (**6a**) was synthesized by two routes; *via* halogenoethylamides (**4a**) and (**5a**) or deprotected *O*-mesylethanolamide (**7a**). The mesylate (**3a**) (20 mmol) was reacted with NaI (100 mmol) in acetone (50 ml) to yield Boc-Val-NHCH₂CH₂I (**4a**), m.p. 123–124 °C (89%), which was deprotected with HCl (4 M) in dioxane (50 ml) to give a hygroscopic powder, $\text{HCl}\cdot\text{H}\cdot\text{Val}\cdot\text{NHCH}_2\text{CH}_2\text{I}$ (**5a**) (95%). Without further purification, the iodoethylamide (**5a**) (10 mmol) was reacted with sodium sulphite (20 mmol) in water (20 ml) to give analytically pure crystalline Val-Tau (**6a**) (81%) {m.p. 318–320 °C (decomp.), $[\alpha]_{\text{D}}^{20} +40.7^\circ$ (*c* 1, H_2O)}. The preparation of (**6a**) from (**7a**) was not so successful. The substitution reaction between (**7a**) (hygroscopic oil, 10 mmol)

and sodium sulphite (20 mmol) in water (20 ml) gave (**6a**), m.p. 317–319 °C (decomp.), in only 10% yield, although (**7a**) was obtained in 97% yield by deprotection of the key intermediate (**3a**). Both samples Val-Tau (**6a**) prepared by the two different routes were identical with the authentic specimen {m.p. 315–316 °C (decomp.), $[\alpha]_{\text{D}}^{20} +40.5^\circ$ (*c* 1, H_2O)}.⁷



Scheme 1. Reagents and conditions: i, NaBH_4 , LiCl , THF, EtOH, room temp., 20 h; ii, MsCl , Et_3N , CH_2Cl_2 , -5°C , 30 min; iii, NaI or LiBr , Me_2CO , room temp.; iv, HCl , dioxane, room temp., 1 h; v, HBr , AcOH , room temp.; vi, Na_2SO_3 , H_2O , room temp., 20 h.

Similarly, Phe-Tau (**6b**) and Ser(Ac)-Tau (**6d**) were prepared from the corresponding dipeptides containing a glycine ethyl ester at the C-terminal [(**1b**) and (**1c**)] by the route shown in Scheme 1; net yields from (**1**) via (**5**) were 32 and 23%, respectively. Although Phe-Tau (**6b**) can be obtained from neither the bromo nor the chloro derivative as previously reported,⁷ iodoethylamide (**5b**) gave (**6b**) {m.p. 305–307 °C (decomp.), $[\alpha]_D^{20} +68.0^\circ$ (c 1, H₂O); [lit.,⁷ m.p. 306–308 °C (decomp.), $[\alpha]_D^{20} +69.2^\circ$ (c 1, H₂O)]}. The naturally occurring Ser-Tau (**6e**) {m.p. 264–266 °C, $[\alpha]_D^{20} +9.6^\circ$ (c 1, H₂O); lit.,⁷ m.p. 265–267 °C (decomp.), $[\alpha]_D^{20} +10.1^\circ$ (c 1, H₂O)]}, was obtained by a mild ethanolic saponification of (**6d**) [prepared by the sequence (**1c**) → (**2c**) → (**3c**) → (**4c**) → (**5d**) → (**6d**)].

Since the methods described herein can be generalized to convert a C-terminal amino acid in general peptides to a corresponding optically active 2-substituted taurine, such a synthetic approach giving a variety of taurine-peptide derivatives is potentially useful.

Received, 28th October 1988; Com. 8/04268C

References

- 1 Á. Furka, F. Sebestyén, L. Feuer, A. Horváth, J. Hercsel, S. Ormai, and B. Bányai, *Acta Biochim. Biophys. Acad. Sci. Hung.*, 1980, **15**, 39.
- 2 K.-M. Marnela and P. Lähdesmäki, *Neurochem. Res.*, 1983, **7**, 933.
- 3 Y. Tomida and H. Kimura, *Acta Histochem. Cytochem.*, 1987, **20**, 31.
- 4 F. Sebestyén, Á. Furka, L. Feuer, J. Gulyás, and Gy. Szókán, *Int. J. Pept. Protein Res.*, 1980, **16**, 245.
- 5 A. M. Felix, *Org. Prep. Proced. Int.*, 1982, **14**, 157.
- 6 M. Altamura and G. Agnes, *J. Org. Chem.*, 1988, **53**, 1307.
- 7 K. Ienaga, K. Higashiura, Y. Toyomaki, H. Matsuura, and H. Kimura, *Chem. Pharm. Bull.*, 1988, **36**, 70.
- 8 K. Ienaga, K. Nakamura, K. Higashiura, Y. Toyomaki, and H. Kimura, *Chem. Pharm. Bull.*, 1988, **36**, 2796.
- 9 S. Ida, K. Kuriyama, Y. Tomida, and H. Kimura, *J. Neuroscience Res.*, 1987, **18**, 4.
- 10 K. Ienaga, K. Higashiura, Y. Toyomaki, Y. Tomida, and H. Kimura, *Peptide Chemistry 1987*, 1988, 791.
- 11 Y. Hamada, M. Shibata, T. Sugiura, S. Kato, and T. Shioiri, *J. Org. Chem.*, 1987, **52**, 1252.